PROTELOS

This brand name is authorized in Estonia, Lithuania, Netherlands, Poland, Tunisia

Active ingredients

The drug PROTELOS contains one active pharmaceutical ingredient (API):

1 Strontium ranelate UNII 04NQ160FRU - STRONTIUM RANELATE

In vitro, strontium ranelate increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture and reduces bone resorption by decreasing osteoclast differentiation and resorbing activity. This results in a rebalance of bone turnover in favour of bone formation. Read about Strontium ranelate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M05BX03	Strontium ranelate	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BX Other drugs affecting bone structure and mineralization
Discover more medicines within M05BX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1186949, 1207808, 1207819, 1207831, 1207842, 1207886
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1004393, 1030475, 1030476, 1030477, 1030478, 1030479
Country: NL	Z-Index G-Standaard	Identifier(s): 15063143
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 78034
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100125796
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 6353141